Hugo Peris, Spiral Therapeutics CEO

Hear­ing-fo­cused biotech grabs trio of pro­grams from Oton­o­my's fire sale

Oton­o­my may be shut­ting down, but the lessons learned there will live on at an­oth­er biotech work­ing on new treat­ments for hear­ing loss.

San Fran­cis­co-based Spi­ral Ther­a­peu­tics has bought cer­tain as­sets re­lat­ed to three of Oton­o­my’s pro­grams, rang­ing from da­ta, patent rights, and know-how to in­ven­to­ry. That in­cludes da­ta around Oton­o­my’s twice-failed lead pro­gram, OTO-104 (Otividex), a sus­tained-ex­po­sure for­mu­la­tion of dex­am­etha­sone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA